Looking at immunotherapy for lung cancer with rare gene mutations
Part of Cancer, Lungs & breathing clinical trials.
This study looks back at patients with advanced non-small cell lung cancer who have specific rare gene changes (mutations). It aims to see how well immunotherapy works for people with these exact mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced non-small cell lung cancer
- Your tumor testing found a confirmed KARS, ALK, ERBB2, MET, RET, or BRAF mutation
- Your diagnosis is non-small cell lung cancer, not small cell lung cancer
- You have records of your cancer diagnosis and mutation test results for study review
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.